Articles

Poll

Podcasts

Slideshows

Videos

In this episode, hosts discuss GLP-1 RA use and CGM technology, updates in once-weekly insulins, the concept of continuous ketone monitoring, and practical application of artificial intelligence into care. 

Diabetes Dialogue: Hot Topics and Updates from ATTD 2024

In this episode, all things AID from the 17th annual ATTD, including updates from Insulet Corporation and Omnipod, study data from the Control IQ algorithm, the SMASH study, and a peak into the future with the Neural Network AID algorithm.

Diabetes Dialogue: All Things AID at ATTD 2024

In this episode, hosts discuss top news and updates in automated insulin delivery from ATTD 2024, with a focus on new data from the T1D Exchange and a read-out from the CRISTAL study. 

Diabetes Dialogue: T1D Glycemic Improvement and CRISTAL at ATTD 2024

In this episode, Neuen talks about the FLOW trial, the concept of 4 pillars of GDMT for CKD in type 2 diabetes, and how to approach sequencing of these therapies.

Diabetes Dialogue: FLOW Trial and Chronic Kidney Disease Updates, with Brendon Neuen, MBBS, PhD

Jake Leach, COO of Dexcom, joins the podcast to discuss the historic clearance of the Stelo sensor and other updates in CGM from the company. 

Diabetes Dialogue: Stelo News and Dexcom CGM Updates, with Jake Leach

The FDA has cleared Sequel's twiist, a novel automated insulin delivery system, expanding patient choice for individuals with type 1 diabetes.

FDA Grants Clearance to Sequel's twiist AID System for Type 1 Diabetes

On March 08, 2024, the FDA approved semaglutide 2.4 mg (Wegovy) to reduce cardiovascular risk in adults with obesity or overweight and heart disease based on the SELECT trial.

Semaglutide (Wegovy) Receives FDA Label Expansion to Include Cardiovascular Risk Reduction

Continuous glucose monitoring was associated with lower odds of diabetic retinopathy development, even after adjusting for hemoglobin A1c levels.

CGM Use in Type 1 Diabetes Management May Mitigate Risk of Retinopathy 

On March 07, 2024, Novo Nordisk provided updates on semaglutide 2.4 mg as well as the development programs cagrisema, monlunabant, and amycretin.

Novo Nordisk Delivers Updates on Development of Semaglutide, CagriSema, Amycretin, and More 

In our endocrinology month in review for February 2024, we are spotlighting trending studies and new data in endocrinology, the latest news surrounding tirzepatide, and a recap of the 4 episodes of our flagship endocrinology podcast launched during the last month.

Endocrinology Month in Review: February 2024

Type 2 Diabetes

Type 1 Diabetes

Polycystic Ovary Syndrome

Hormonal Disorders

Thyroid Disorders

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.